**Background**

Anaplastic lymphoma kinase (ALK)-inhibitors are indicated in adult patients with ALK-positive advanced NSCLC, being ceritinib indicated as first line. Hepatotoxicity has been described for crizotinib,1,2 and ceritinib.3

3. Product Information Zykdia (TM) ceritinib oral capsules. Novartis Pharmaceuticals Corporation; East Hanover, NJ; 2014

**Purpose**

To describe a case of alectinib hepatotoxicity in a patient with hepatotoxicity background with other ALK-inhibitors

**Materials & Methods**

- The data were obtained by reviewing the electronic medical records
- Karch-Lasagna, Naranjo and WHO-UMC algorithms have been used

**Results**

<table>
<thead>
<tr>
<th>14/09/16</th>
<th>Disease onset</th>
<th>ALK+ NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Conclusions</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
- Alectinib may be a therapeutic option in patients with ALK-positive NSCLC who have developed liver toxicity to other ALK-inhibitors. Further follow-up is needed to ratify this statement.
- Karch-Lasagna and Naranjo algorithms established a “probable” relationship between hepatotoxicity and Crizotinib/Ceritinib.
- WHO-UMC algorithm established this relationship as “probable” to crizotinib and “certain” to ceritinib.
- Hepatic toxicity to ALK-inhibitors frequently shows a reversible pattern and transaminases and prothrombin time appear to be the most sensitive markers.

---

- **Background**
- **Purpose**
- **Materials & Methods**
- **Results**
- **Conclusions**